Test report, University of Helsinki and Clean Touch Medical

University of Helsinki has tested the capability of COVIDSAFE to inactivate SARS-Cov-2 virus. The testing was performed in a biosafety-level-3 (BSL-3) laboratory with live SARS-CoV-2 from a cultured virus sample. The virus sample was applied on the COVIDSAFE surface as well as control materials, and allowed to air-dry in room temperature for 60 minutes or 210 minutes. After this incubation time, a sample from the virus was added to susceptible cultured cells and the virus viability was tested by allowing virus to infect the cells for the duration of at least 5 days. During this time, if the virus is viable, it should cause a visible cytopathic effect on the cultured cells. Additionally, all samples were checked with RT-PCR to measure the level of viral RNA copies (relative quantitation).

The results are given as “Inactivated” or “Viable virus detected”. “Inactivated” means that the virus was totally inactivated, and no signs of virus growth were observed in cultured cells after the treatment.

SURFACE MATERIALRESULT
COVIDSAFEInactivated at 60 minutes
COVIDSAFE (used)Inactivated at 60 minutes
Material 1Viable virus detected
Material 2*Viable virus detected at 60 minutes, Inactivated at 210 minutes
Material 3*Inactivated at 60 minutes
Material 2*Viable virus detected
Material 3*Inactivated at 60 minutes (but also toxic to cells)
Material 6Viable virus detected
Plastic cell culture plateViable virus detected
* surface material known to have antiviral properties

Together these findings may be taken to show that in the conditions tested, COVIDSAFE completely inactivates the SARS-CoV-2 virus within 60 minutes.

It should be noted however, that the test result may not be the same if tested using other incubation times or conditions. It should also be noted that both virus concentrations tested here are considerably higher than those typically observed in non-laboratory conditions. This was done in order to give the surface material a ‘maximum’ challenge in this test.

Tarja Sironen, PhD Associate Professor of Emerging infections Faculties of Medicine and Veterinary Medicine University of Helsinki